Alhashem Fatema, Tiren-Verbeet Nicolette Leonie, Alp Emine, Doganay Mehmet
Fatema Alhashem, Department of Pediatrics, King Hamad University Hospital, Busaiteen 24343, Muharraq, Bahrain.
World J Clin Cases. 2017 Aug 16;5(8):324-332. doi: 10.12998/wjcc.v5.i8.324.
Sepsis is one of the major challenges of today. Although gram-positive bacteria related infections are more prevalent in hospital setting, the highest mortality rate is associated with gram-negative microorganisms especially . , including Escherichia coli, Klebsiella spp., Proteus spp., Enterobacter spp. and Serratia spp. Resistance to β-lactams in is primarily attributed to the production of B-lactamase enzymes with subsequent antibiotic hydrolysis and to a lesser extent by alteration of efflux pump or porins expression. Carbapenem resistant (CRE) and are the most notorious pathogens due to the high incidence of morbidity and mortality especially in the immunocompromised patients in the intensive care unit. The most appropriate antimicrobial therapy to treat CRE is still controversial. Combination therapy is preferred over monotherapy due to its broad-spectrum coverage of micro-organisms, due to its synergetic effect and to prevent development of further resistance. Current suggested therapies for CRE resistance as well as promising antibiotics that are currently under investigation for winning the war against the emerging CRE resistance are reviewed and discussed.
脓毒症是当今的主要挑战之一。尽管革兰氏阳性菌相关感染在医院环境中更为普遍,但最高死亡率与革兰氏阴性微生物有关,尤其是大肠杆菌、克雷伯菌属、变形杆菌属、肠杆菌属和沙雷菌属。革兰氏阴性菌对β-内酰胺类药物的耐药性主要归因于β-内酰胺酶的产生以及随后的抗生素水解,在较小程度上还归因于外排泵或孔蛋白表达的改变。耐碳青霉烯类革兰氏阴性菌(CRE)是最臭名昭著的病原体,因为发病率和死亡率很高,尤其是在重症监护病房的免疫功能低下患者中。治疗CRE的最合适抗菌疗法仍存在争议。联合治疗优于单一治疗,因为它对微生物具有广谱覆盖,具有协同作用,并能防止进一步耐药性的产生。本文综述并讨论了目前针对CRE耐药性的建议疗法以及目前正在研究的有望战胜新出现的CRE耐药性的抗生素。